Literature DB >> 8214274

Increased serum phospholipase A2 activity in Malawian children with falciparum malaria.

P Vadas1, T E Taylor, L Chimsuku, D Goldring, E Stefanski, W Pruzanski, M E Molyneux.   

Abstract

Some clinical manifestations of severe malaria resemble those of sepsis and there may be mediators of the host response that are common to both sepsis and malaria. Phospholipase A2 (PLA2), a proinflammatory enzyme whose expression is induced by tumor necrosis factor (TNF), has been implicated in the pathogenesis of complications of the sepsis syndrome. We examined levels of circulating PLA2 in Plasmodium falciparum malaria and studied the association of PLA2 with disease severity. Plasma PLA2 and TNF were measured in 75 Malawian children with P. falciparum malaria. The mean (SD) plasma PLA2 activity in children with acute malaria was 53,804 (37,256) units/ml as compared with 424 (349) units/ml in 34 healthy controls (P < 0.00001). The mean PLA2 activity in 45 convalescent patients was 2,546 (7,372) units/ml (P < 0.00001). In 48 patients with pretreatment PLA2 activity less than 60,000 units/ml, mortality was 8.3%, while in 27 patients with pretreatment PLA2 levels greater than 60,000 units/ml, mortality was 33.3% (P = 0.008). There were significant correlations between PLA2 and TNF (r = 0.471, P < 0.01), density of parasitemia (r = 0.443, P < 0.0001) and a decrease in hematocrit (r = 0.352, P < 0.005). These data show that P. falciparum malaria is associated with a markedly increased circulating PLA2, especially in patients with severe disease, as manifested by high parasite burden, anemia, coma, and death.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8214274     DOI: 10.4269/ajtmh.1993.49.455

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  6 in total

1.  In vitro anti-Plasmodium falciparum properties of the full set of human secreted phospholipases A2.

Authors:  Carole Guillaume; Christine Payré; Ikram Jemel; Louise Jeammet; Sofiane Bezzine; Gajendra S Naika; James Bollinger; Philippe Grellier; Michael H Gelb; Joseph Schrével; Gérard Lambeau; Christiane Deregnaucourt
Journal:  Infect Immun       Date:  2015-03-30       Impact factor: 3.441

2.  Antimalarial Activity of Human Group IIA Secreted Phospholipase A2 in Relation to Enzymatic Hydrolysis of Oxidized Lipoproteins.

Authors:  Mélanie Dacheux; Véronique Sinou; Christine Payré; Louise Jeammet; Daniel Parzy; Philippe Grellier; Christiane Deregnaucourt; Gérard Lambeau
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

3.  Serum amyloid A protein enhances the activity of secretory non-pancreatic phospholipase A2.

Authors:  W Pruzanski; F C de Beer; M C de Beer; E Stefanski; P Vadas
Journal:  Biochem J       Date:  1995-07-15       Impact factor: 3.857

4.  Association of carotid plaque Lp-PLA(2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke.

Authors:  Berna Atik; S Claiborne Johnston; Deborah Dean
Journal:  PLoS One       Date:  2010-06-09       Impact factor: 3.240

5.  Lipid metabolites of the phospholipase A2 pathway and inflammatory cytokines are associated with brain volume in paediatric cerebral malaria.

Authors:  Vasiliki Pappa; Karl Seydel; Sanchit Gupta; Catherine M Feintuch; Michael J Potchen; Samuel Kampondeni; Adam Goldman-Yassen; Mike Veenstra; Lillie Lopez; Ryung S Kim; Joan W Berman; Terrie Taylor; Johanna P Daily
Journal:  Malar J       Date:  2015-12-21       Impact factor: 2.979

6.  Inhibition of the activity of pro-inflammatory secretory phospholipase A(2) by acute phase proteins.

Authors:  W Pruzanski; E Stefanski; P Vadas
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.